DeepMed Research

Miltenyi Biomedicine GmbH

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Private

Established: 2019-01-01

Employees: 51

Market Cap: -

Website: http://www.miltenyibiomedicine.com

Clinical Trials

US Zamto-cel Autoimmune Diseases

Phase 1

Not yet recruiting

Conditions: Lupus Nephritis
Systemic Lupus Erythematosus
Systemic Sclerosis (SSc)
Diffuse Cutaneous Systemic Sclerosis

Interventions: Biological: zamtocabtagene autoleucel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2024-11-27

Last Posted Date: 2024-11-27

Lead Sponsor: Miltenyi Biomedicine GmbH

Target Recruit Count: 48

Registration Number: NCT06708845

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

Not Applicable

Recruiting

Conditions: Childhood Non-Hodgkin Lymphoma
Chronic Lymphatic Leukemia
Melanoma Stage III
Melanoma Stage IV
Acute Lymphatic Leukemia
B-cell Non Hodgkin Lymphoma
Pediatric ALL

Interventions: Biological: MB-CART19.1
Biological: MB-CART20.1
Biological: MB-CART2019.1

First Posted Date: 2024-07-18

Last Posted Date: 2024-07-22

Lead Sponsor: Miltenyi Biomedicine GmbH

Target Recruit Count: 40

Registration Number: NCT06508775

Locations: 🇩🇪
Universitätsklinikum Köln, Cologne, Germany
🇩🇪
Universitätsmedizin Göttingen, Göttingen, Germany
🇩🇪
Universitätsklinikum Münster, Münster, Germany

and more 1 locations

Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With Relapsed or Refractory B-Cell Neoplasms

Phase 2

Not yet recruiting

Conditions: B-Cell Neoplasm

Interventions: Drug: zamtocabtagene autoleucel (MB-CART2019.1)

First Posted Date: 2024-07-18

Last Posted Date: 2025-05-14

Lead Sponsor: Miltenyi Biomedicine GmbH

Target Recruit Count: 31

Registration Number: NCT06508931

MB-dNPM1-TCR.1 in Relapsed/refractory AML

Phase 1

Recruiting

Conditions: Leukemia, Myeloid, Acute

Interventions: Biological: MB-dNPM1-TCR.1

First Posted Date: 2024-05-22

Last Posted Date: 2024-11-21

Lead Sponsor: Miltenyi Biomedicine GmbH

Target Recruit Count: 29

Registration Number: NCT06424340

Locations: 🇳🇱
Leiden University Medical Center, Leiden, Netherlands

M-2018-334 in Hematological Malignancies

Not Applicable

Not yet recruiting

Conditions: Hematological Malignancies

Interventions: Device: CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version)

First Posted Date: 2024-01-25

Last Posted Date: 2025-05-14

Lead Sponsor: Miltenyi Biomedicine GmbH

Target Recruit Count: 18

Registration Number: NCT06225050

MB-CART19.1 in Refractory SLE

Phase 1

Recruiting

Conditions: SLE - Systemic Lupus Erythematosus

Interventions: Biological: MB-CART19.1

First Posted Date: 2024-01-03

Last Posted Date: 2024-09-30

Lead Sponsor: Miltenyi Biomedicine GmbH

Target Recruit Count: 29

Registration Number: NCT06189157

Locations: 🇩🇪
Universitätsklinikum Erlangen, Medizinische Klinik 3, Erlangen, Germany
🇩🇪
Otto-von-Guericke-Universität Magdeburg, Magdeburg, Germany
🇩🇪
Universitatsklinikum Tubingen - Medizinische Universitätsklinik Abt. II, Tübingen, Germany

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

Recruiting

Conditions: Non Hodgkin Lymphoma

Interventions: Other: Long-term Follow-Up

First Posted Date: 2023-11-03

Last Posted Date: 2024-11-20

Lead Sponsor: Miltenyi Biomedicine GmbH

Target Recruit Count: 150

Registration Number: NCT06116110

Locations: 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States

and more 2 locations

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Phase 2

Active, not recruiting

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Genetic: MB-CART2019.1
Drug: R-GemOx or BR plus polatuzumab vedotin

First Posted Date: 2021-04-14

Last Posted Date: 2025-03-12

Lead Sponsor: Miltenyi Biomedicine GmbH

Target Recruit Count: 168

Registration Number: NCT04844866

Locations: 🇪🇸
Hospital Clinic de Barcelona (Hospital Clinic i Provincial), Barcelona, Spain
🇦🇹
Medizinische Universitaetsklinik Graz, Graz, Austria
🇦🇹
Universitatsklinikum Innsbruck Universitatsklinik fur Innere Medizin V, Innsbruck, Austria

and more 50 locations

DALY II USA/ MB-CART2019.1 for DLBCL

Phase 2

Recruiting

Conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Relapsed Diffuse Large B Cell Lymphoma
High Grade B-cell Lymphoma (HGBCL)
Primary Mediastinal B-cell Lymphoma (PMBCL)
Transformed Lymphoma
Central Nervous System Lymphoma
Mantle Cell Lymphoma (MCL)
Richter Transformation

Interventions: Biological: zamtocabtagene autoleucel (MB-CART2019.1)
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Bendamustine

First Posted Date: 2021-03-11

Last Posted Date: 2025-04-24

Lead Sponsor: Miltenyi Biomedicine GmbH

Target Recruit Count: 248

Registration Number: NCT04792489

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 21 locations

A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers

Completed

Conditions: COVID-19

Interventions: Procedure: Blood sampling
Procedure: Throat swab

First Posted Date: 2020-05-28

Last Posted Date: 2022-05-25

Lead Sponsor: Miltenyi Biomedicine GmbH

Target Recruit Count: 417

Registration Number: NCT04405466

Locations: 🇩🇪
Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, NRW, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy